Gold Standard™ Organization Introduction
"A generic oncology drug treatment is now available within many of the major cancer typology and this is often the 'gold standard' option for this condition. Opportunities exist to recommend schedules that encourage initiation of treatment with these 'gold standard' generic medicines. This is a positive sign which should increase the uptake of these drugs and potentially generate long-term savings through the use of a safe and effective therapy at an affordable price".
Taj Oncology Corporation in the United States qualified for the CEO Cancer Gold Standard™ Accreditation, bestowed for the first time by the CEO Roundtable on Cancer.
Taj Oncology participates in the CEO Roundtable on Cancer with 40 other companies, federal agencies, and nonprofits. Members play a prominent role in the national effort to eradicate cancer, working together to identify opportunities that will:
- Lower the risk of cancer.
- Enable early diagnosis.
- Facilitate better access to the best available treatments.
- Hasten the discovery of novel and more effective diagnostic tools and anticancer therapies.
The CEO Cancer Gold Standard is a series of cancer-related recommendations that address 3 goals:
- Risk reduction
- Early selection
- Quality care
To become accredited, organizations must demonstrate a culture that fosters healthy lifestyles and provides support when a diagnosis of cancer becomes a reality. They also need to provide programs and benefits that lower cancer risk, attempt to detect it earlier, and provide access to high-quality treatment, including clinical trials.
Taj Oncology always has been a leader in these areas. Several of the programs and policies in the Gold Standard criteria were already in place when Taj joined the Roundtable. The Gold Standard encourages Taj Oncology to do an even better job educating its employees about these services and educational opportunities.
Taj Oncology is committed to keeping its employees and their families informed about advances in cancer prevention and treatment, and will continue to enhance and improve the programs and policies that earned the company the Gold Standard accreditation.
Taj Pharma Group
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.
Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.
While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today." We have already progressed on such efforts by our current presence in more than 40 countries.